Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07285018 · ClinicalTrials.gov registry record · Phase 2
A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain
A Phase 2 study of Diabetic Peripheral Neuropathic Pain, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 20
- Study locations
NCT07285018: Recruiting Phase 2 study of Diabetic Peripheral Neuropathic Pain, sponsored by Eli Lilly and Company.
NCT07285018 is a Phase 2 study of Diabetic Peripheral Neuropathic Pain that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 150 participants, below the 416-participant average among 7 other Diabetic Peripheral Neuropathic Pain trials with a reported enrollment target (64% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07285018, a Phase 2 study of Diabetic Peripheral Neuropathic Pain, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to test the safety and efficacy of study drug LY4065967 for the treatment of diabetic peripheral neuropathic pain (DPNP). This trial is part of the chronic pain master protocol H0P-MC-CPMP (NCT05986292) which is a protocol to accelerate the development of new treatments for chronic pain.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LY4065967
Study Locations (20)
Florida
- Bradenton Research Center, Inc. - Bradenton
- Accel Research Sites - DeLand Clinical Research Unit - DeLand
- K2 MEDICAL Research THE VILLAGES - Lady Lake
- K2 Medical Research ORLANDO - Maitland
- Merritt Island Medical Research, LLC - Merritt Island
- Suncoast Research Group - Miami
- New Horizon Research Center - Miami
- Suncoast Clinical Research, Inc. - New Port Richey
- Renstar Medical Research - Ocala
- Precision Clinical Research - Sunrise
- Charter Research - Lady Lake - The Villages
- Conquest Research - Winter Park
California
- Desert Oasis Healthcare Medical Group - Palm Springs
- Artemis Institute for Clinical Research - Riverside
- Artemis Institute for Clinical Research - San Diego
Arizona
- Synexus Clinical Research US, Inc. - Phoenix
- Arizona Research Center - Phoenix
Alabama
- Central Research Associates - Birmingham
Connecticut
- CMR of Greater New Haven - Hamden
Georgia
- North Georgia Clinical Research - Woodstock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2026-02-16 |
| Est. Completion | 2027-07 |
| Phase | Phase 2 |
What NCT07285018 shows while recruiting
NCT07285018 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 416-participant average among 7 other Diabetic Peripheral Neuropathic Pain trials with a reported enrollment target (64% lower).
The record links to 1 condition, with Diabetic Peripheral Neuropathic Pain appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07285018 names 20 study sites across 6 states, led by Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT07285018 about?
NCT07285018 is a clinical study titled "A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain". The purpose of this study is to test the safety and efficacy of study drug LY4065967 for the treatment of diabetic peripheral neuropathic pain (DPNP). This trial is part of the chronic pain master protocol H0P-MC-CPMP (NCT05986292) which is a protocol to accelerate the development of new treatments ...
What is the current status of trial NCT07285018?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2026-02-16. Estimated completion is 2027-07.
What conditions does trial NCT07285018 study?
This clinical trial studies the following conditions: Diabetic Peripheral Neuropathic Pain.
What interventions are being tested in trial NCT07285018?
The interventions under investigation include: Placebo (DRUG), LY4065967 (DRUG).
Who is sponsoring clinical trial NCT07285018?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07285018 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Peripheral Neuropathic Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy
RECRUITING · Phase 2
-
A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Diabetic Peripheral Neuropathic Pain (NP05).
COMPLETED · Phase 2
-
Efficacy and Safety of ETX-018810 for the Treatment of Diabetic Peripheral Neuropathic Pain
COMPLETED · Phase 2
-
MAD Study to Assess the Safety, Tolerability, PKs and Efficacy of YJ001 for Spray Use in Patients With DPNP
RECRUITING · Phase 1
-
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
RECRUITING · Phase 3
-
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI